Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: A phase II trial

Darrell J. White; Nizar J. Bahlis; Deb C. Marcellus; Andrew Belch; A. Keith Stewart; Christine Chen; Michael J. Kovacs; David A. MacDonald; Donna E. Reece; Tony Reiman; Erica Harnett; Ralph M. Meyer; Judy Anne W. Chapman; Stephen Couban

doi:10.1016/j.clml.2012.08.009

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: A phase II trial

Darrell J. White, Nizar J. Bahlis, Deb C. Marcellus, Andrew Belch, A. Keith Stewart, Christine Chen, Michael J. Kovacs, David A. MacDonald, Donna E. Reece, Tony Reiman, Erica Harnett, Ralph M. Meyer, Judy Anne W. Chapman, Stephen Couban

科研成果: 期刊稿件 › 文章 › 同行评审

2 引用（Scopus）

源语言	英语
页（从-至）	19-24
页数	6
期刊	Clinical Lymphoma, Myeloma and Leukemia
卷	13
期	1
DOI	https://doi.org/10.1016/j.clml.2012.08.009
出版状态	已出版 - 2月 2013
已对外发布	是

!!!ASJC Scopus Subject Areas

血液学
肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/j.clml.2012.08.009

其它文件与链接

引用此

White, D. J., Bahlis, N. J., Marcellus, D. C., Belch, A., Stewart, A. K., Chen, C., Kovacs, M. J., MacDonald, D. A., Reece, D. E., Reiman, T., Harnett, E., Meyer, R. M., Chapman, J. A. W., & Couban, S. (2013). Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: A phase II trial. Clinical Lymphoma, Myeloma and Leukemia, 13(1), 19-24. https://doi.org/10.1016/j.clml.2012.08.009

White, DJ, Bahlis, NJ, Marcellus, DC, Belch, A, Stewart, AK, Chen, C, Kovacs, MJ, MacDonald, DA, Reece, DE, Reiman, T, Harnett, E, Meyer, RM, Chapman, JAW & Couban, S 2013, 'Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: A phase II trial', Clinical Lymphoma, Myeloma and Leukemia, 卷 13, 号码 1, 页码 19-24. https://doi.org/10.1016/j.clml.2012.08.009

@article{df29e913fe1c45c0bc2aadf20d71bfd2,

title = "Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: A phase II trial",

author = "White, {Darrell J.} and Bahlis, {Nizar J.} and Marcellus, {Deb C.} and Andrew Belch and Stewart, {A. Keith} and Christine Chen and Kovacs, {Michael J.} and MacDonald, {David A.} and Reece, {Donna E.} and Tony Reiman and Erica Harnett and Meyer, {Ralph M.} and Chapman, {Judy Anne W.} and Stephen Couban",

note = "Funding Information: Drs White, Bahlis, Chen, Macdonald, Reece, Reiman, and Meyer have received honoraria and research funding from Celgene Corporation. Dr Belch has received research funding from Celgene Corporation. Dr Stewart has received honoraria from Celgene Corporation. All other authors have stated that they have no conflicts of interest. Funding Information: This work was supported by a grant to the NCIC CTG from the Canadian Cancer Society Research Institute (grant 21,039 ). Lenalidomide was provided by Celgene Corporation (Summit, NJ). ",

year = "2013",

month = feb,

doi = "10.1016/j.clml.2012.08.009",

language = "English",

volume = "13",

pages = "19--24",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "1",

}

TY - JOUR

T1 - Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma

T2 - A phase II trial

AU - White, Darrell J.

AU - Bahlis, Nizar J.

AU - Marcellus, Deb C.

AU - Belch, Andrew

AU - Stewart, A. Keith

AU - Chen, Christine

AU - Kovacs, Michael J.

AU - MacDonald, David A.

AU - Reece, Donna E.

AU - Reiman, Tony

AU - Harnett, Erica

AU - Meyer, Ralph M.

AU - Chapman, Judy Anne W.

AU - Couban, Stephen

N1 - Funding Information: Drs White, Bahlis, Chen, Macdonald, Reece, Reiman, and Meyer have received honoraria and research funding from Celgene Corporation. Dr Belch has received research funding from Celgene Corporation. Dr Stewart has received honoraria from Celgene Corporation. All other authors have stated that they have no conflicts of interest. Funding Information: This work was supported by a grant to the NCIC CTG from the Canadian Cancer Society Research Institute (grant 21,039 ). Lenalidomide was provided by Celgene Corporation (Summit, NJ).

PY - 2013/2

Y1 - 2013/2

UR - http://www.scopus.com/inward/record.url?scp=84873282832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873282832&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.08.009

DO - 10.1016/j.clml.2012.08.009

M3 - Article

C2 - 23141150

AN - SCOPUS:84873282832

SN - 2152-2650

VL - 13

SP - 19

EP - 24

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 1

ER -

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: A phase II trial

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此